Treatment of Epithelial Fragility Disorders
The present invention provides compounds which modulate the expression of keratin genes, particularly mutated or defective keratin genes, for treating epithelial fragility disorders such as Meesmann Epithelial Corneal Dystrophy (MECD).
MCLEAN IRWIN [GB]; LIAO HAIHUI [GB]
Type of Offer:
« More Genetics Patents